ChromaDex Corporation

CDXC | $3.85 1.58% 120K

(0.0% 1d) (28.8% 1m) (177.5% 1y) (0.0% 2d) (0.0% 3d) (0.3% 7d) (7.57% volume)
Earnings Calendar: 2024-03-06
Market Cap: $ 289,940,104
http://www.chromadex.com
Sec Filling | Patents | 110 employees

Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.

food

add to watch list Paper trade email alert is off

Press-releases

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
Published: 2024-02-21 (Crawled : 15:30) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 147.8% | O: -1.89% H: 2.56% C: -2.56%
report financial results

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
Published: 2024-02-05 (Crawled : 15:00) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 159.21% | O: -1.97% H: 5.37% C: 4.03%

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
Published: 2024-01-26 (Crawled : 23:00) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 168.03% | O: 1.36% H: 3.97% C: 2.68%
conference

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+
Published: 2023-12-12 (Crawled : 15:30) - prnewswire.com
CDXC | $3.85 1.58% 120K

Process Industries

| 191.85% | O: -0.74% H: 0.75% C: 0.0%
health

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 196.24% | O: 4.51% H: 2.16% C: 0.0%
niagen trial milestone

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR)
Published: 2023-11-15 (Crawled : 15:00) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 187.59% | O: 1.46% H: 10.79% C: 7.91%
niagen study

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
Published: 2023-11-09 (Crawled : 15:30) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 146.25% | O: 0.0% H: 0.0% C: -11.25%

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
Published: 2023-10-31 (Crawled : 19:00) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 198.48% | O: -0.76% H: 0.76% C: 0.76%
report financial results

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series
Published: 2023-08-07 (Crawled : 13:00) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 140.24% | O: 0.0% H: 0.0% C: -1.22%

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
Published: 2023-08-02 (Crawled : 13:00) - biospace.com/
CDXC | $3.85 1.58% 120K

Process Industries

| 130.41% | O: -0.58% H: 0.59% C: -0.59%
report financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001628280-24-006725	4	2024-02-24	2024-02-22	Buy	A	213886	213886
0001628280-24-006724	4	2024-02-24	2024-02-22	Buy	A	399568	399568
0000899243-23-018667	4	2023-09-07	2023-09-06	Buy	P	3467778	11408715
0001628280-23-029599	4	2023-08-16	2023-08-12	Sell	M	22436	44872
0001628280-23-029599	4	2023-08-16	2023-08-12	Buy	M	22436	22436